Gan & Lee Pharmaceuticals. (SHA: 603087)

China flag China · Delayed Price · Currency is CNY
49.80
+0.25 (0.50%)
Nov 11, 2024, 3:00 PM CST
2.24%
Market Cap 29.66B
Revenue (ttm) 2.95B
Net Income (ttm) 580.86M
Shares Out 597.09M
EPS (ttm) 0.99
PE Ratio 50.39
Forward PE 31.85
Dividend 0.20 (0.40%)
Ex-Dividend Date Jun 18, 2024
Volume 10,821,235
Open 49.00
Previous Close 49.55
Day's Range 48.88 - 50.14
52-Week Range 32.10 - 62.90
Beta 1.62
Analysts n/a
Price Target n/a
Earnings Date Oct 28, 2024

About Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; ... [Read more]

Sector Healthcare
Founded 1998
Employees 4,482
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603087
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.